AIDOT, Seoul (2026)

28/09/2026

📢 AIDOT Mongolia Launches 'Cerviray AI' Project at 'MHT EXPO 2026' – Gaining High Interest from Mongolian Parliament

We are thrilled to share that AIDOT Mongolia officially presented its integrated AI cervical cancer screening and treatment solution at MHT EXPO 2026 (Mongolia Health Technology Expo 2026), gaining significant attention from key Mongolian lawmakers and healthcare officials!

Dr. Bayar (Dr. Bayarsaikhan), Head of AIDOT Mongolia, officially invited Mongolian Member of Parliament J. Zolzargal to the AIDOT booth (B52). During the visit, MP Zolzargal praised AIDOT’s technology for its real-world applicability and medical innovation, emphasizing the critical role of combining mobile technology, AI, and telemedicine for early screening, diagnosis, and treatment.

💡 Key Highlights of the Integrated Solution:
Bridging Healthcare Disparities: The project led by Dr. Bayar will be introduced to rural Soms (county/township-level administrative units) across Mongolia.

One-Stop Care for Rural Women: Women in remote areas can now access early screening through treatment locally without traveling long distances to urban general hospitals, drastically reducing their financial and logistical burdens.

Vision for a Cervical Cancer-Free Nation: With strong political and institutional support, AIDOT Mongolia is accelerating its nationwide project: "Cervical Cancer-Free Mongolia."

"The successful expo hosting and visits from key political leaders give strong momentum to advancing AI healthcare solutions and realizing our 'Cervical Cancer-Free Mongolia' initiative."

— Dr. Bayar, Head of AIDOT Mongolia

AIDOT remains committed to delivering clinical-grade medical AI technology to improve lives and healthcare access worldwide!

📰 Source: Korea Economic TV (Reported by Deputy Director Jae-jun Yang | September 28, 2026)

23/09/2026

🌐 AIDOT Signs Exclusive Supply Agreement with China’s Guorun International for ‘Cerviray AI’
🤝 Targeting the Hainan Boao Lecheng Pilot Zone and Upcoming Expo Presentation

AIDOT (CEO Jae-hoon Jeong) announced on September 23 that it has signed an exclusive supply agreement with China's Guorun International Medical Group for its AI-powered cervical cancer diagnostic solution, Cerviray AI, following a rigorous evaluation of its clinical accuracy.

The partners are prioritizing registration within the Hainan Boao Lecheng International Medical Tourism Pilot Zone—China’s premier special zone for innovative medical devices. They aim to complete initial clinical applications ahead of registration and will unveil the results at the 2nd Boao Lecheng International Innovative Drugs and Medical Devices Expo on November 20, where AIDOT has been officially invited to present.

AIDOT CTO Hansol Choi stated, "This partnership validates Cerviray AI's clinical utility through rigorous verification, and we will use our Lecheng pilot zone registration and expo presentation as stepping stones for a full-scale entry into the Chinese market."

Source: Korea Economic TV (Reported by Deputy Director Jae-jun Yang | September 23, 2026)

16/09/2026

🌐 AIDOT’s Cerviray AI Accelerates PoC and Global Expansion in Mongolia
🤝 Leveraging On-Device AI to Overcome Remote Barriers and Data Regulations

AIDOT is accelerating its local proof-of-concept and global expansion in Mongolia with its AI-powered cervical cancer screening system, Cerviray AI, through the 2026 Gangwon AI Healthcare Global Innovation Special Zone Project.

Partnering with over five major Mongolian hospitals—including ACH International Hospital and Allergy-Med Hospital, and backed by local medical leader Dr. Bayar—AIDOT aims to build over 50,000 real-world data sets reflecting extreme field conditions like power instability.

Unlike traditional cloud systems, the on-device Cerviray AI operates independently on local terminals without connecting to a server, making it ideal for remote steppes or deserts. Using Self-Supervised Learning, original medical data remains on-device for local processing and de-identification, with only model weights exchanged. This ensures full compliance with international data sovereignty regulations like GDPR.

"This project combines the noble legacy of Dr. Bayar’s family with AIDOT’s on-device AI technology to create an unprecedented success story," said Young-seung Cho, Head of Sales at AIDOT.

Source: Korea Economic TV (Reported by Deputy Director Jae-jun Yang | September 15, 2026)

07/09/2026

📢 Prof. Young Eun Yoon’s Team at Hanyang Univ. Hospital & AIDOT to Present Joint AI Research on Kidney Stone Detection at ISU 2026

We are proud to share that a joint research project on AI-powered kidney stone detection—conducted by Professor Young Eun Yoon’s team at Hanyang University Hospital and AIDOT—has been accepted for a poster presentation at the 15th International Symposium on Urolithiasis (ISU 2026). 🤝

Hosted by the International Urolithiasis Society, ISU 2026 is a premier international academic conference in the field of urolithiasis, taking place October 1–2 at Northwestern University Feinberg School of Medicine in Chicago, Illinois.

💡 About the Research:
📖 Paper Title: "Integrating KUB Anatomical Priors into CT Foundation Model to Enhance Urinary Stone Detection in Non-Contrast CT"
🔬 Key Innovation: The study introduces a novel methodology that integrates anatomical priors learned from plain abdominal X-ray (KUB) images into a CT foundation model to significantly improve stone detection accuracy on non-contrast CT scans.
👥 Role Distribution: Prof. Yoon’s team led the study design, clinical validation, and anatomical criteria establishment, while Dr. Hansol Choi, CTO and Head of AI Research at AIDOT, spearheaded the model implementation, training, and performance verification using AIDOT's proprietary analysis engine.

💬 Key Quotes:
"Urinary stone disease has high recurrence rates and frequently requires emergency room visits, making both speed and diagnostic precision clinically vital. This study helps close diagnostic blind spots in non-contrast CT readings."
— Prof. Young Eun Yoon, Hanyang University Hospital
"Having our joint X-ray and CT AI technology validated on an international academic stage, we will leverage our secured patents and clinical research outcomes to actively expand into global markets, including the U.S."
— Dr. Hansol Choi, CTO of AIDOT

AIDOT continues to push the boundaries of clinical AI innovation. Stay tuned for more updates from ISU 2026! 🚀

📰 Source: Korea Economic TV (Reported by Deputy Director Jae-jun Yang | September 7, 2026)

27/08/2026

🌐 AIDOT’s ‘URO dot AI’ Gains Official Non-covered Status as an Innovative Medical Technology
🤝 Accelerating Commercial Adoption in Clinical Practice

AIDOT (CEO Jae-hoon Jeong) announced that its AI-powered urolithiasis diagnostic support solution, URO dot AI, has officially entered the non-reimbursable health insurance market following a notice revision by the Ministry of Health and Welfare.

Effective September 1 nationwide, medical staff can now officially prescribe and bill for diagnostic support utilizing URO dot AI when assessing patients suspected of having urolithiasis.

Traditional methods require visually reviewing hundreds of non-contrast CT cross-sections, risking delays or missed micro-stones under 4mm. AIDOT’s URO dot AI solves this by performing a 3-dimensional anatomical analysis of the urinary system, precisely pinpointing micro-stones under 4mm within 5 minutes. Clinical studies have demonstrated a high accuracy exceeding 96%.

This milestone removes previous barriers to hospital adoption caused by a lack of billing options, which is expected to accelerate implementation across urology clinics and university hospital emergency rooms. Building on this listing, AIDOT is also pursuing research to expand its diagnostics into an X-ray version through a regional project.

Source: Korea Economic TV (Reported by Deputy Director Jae-jun Yang | August 26, 2026)

13/08/2026

🌐 AIDOT Signs Strategic Partnership with the Government of Tarija, Bolivia
🤝 Supplying Cerviray AI to National Hospitals to Expand Public Healthcare Access

AIDOT (CEO Jae-hoon Jeong), a specialized medical AI solutions company, announced on August 13 that it has signed an official healthcare agreement at the state government level in Bolivia to supply its AI-powered cervical cancer diagnostic solution, Cerviray AI, to national hospitals.

AIDOT entered into this strategic partnership with the Autonomous Departmental Government of Tarija, Bolivia, through a collaborative agreement involving Professor Young-hyun Yoon’s research team at Myongji Junior College and Next Bridge.

Under the agreement, AIDOT's medical solutions will be installed in major national hospitals across the Tarija region for full-scale pilot operations and diagnostic services.

This agreement was driven by the goal of improving health and welfare for vulnerable populations—such as local women and children with limited access to advanced medical infrastructure—by combining cutting-edge AI health technology with public healthcare services.

During the demonstration event, AIDOT’s Cerviray AI diagnostic devices and systems were unveiled, receiving an enthusiastic response from state government officials and national hospital medical staff.

Professor Young-hyun Yoon of Myongji Junior College stated, "It is deeply meaningful to introduce innovative medical AI technology to the people of Bolivia and provide direct assistance. We will continue to expand our positive impact by delivering life-saving technology to medically underserved regions around the world."

Source: Korea Economic TV (Reported by Deputy Director Jae-jun Yang | August 13, 2026)

11/08/2026

🌐 AIDOT Signs Strategic Exclusive Supply Agreement for ‘Cerviray AI’ with China’s Guorun International Medical Group
🤝 Securing a Foothold in the Hainan Medical Free Trade Zone with a 5-Year Partnership

AIDOT (CEO Jae-hoon Jeong), a specialized medical AI diagnostic solutions company, announced on August 11 that it has signed a strategic exclusive supply agreement with Guorun International Medical Group, a leading medical device company in China’s Hainan Medical Free Trade Zone, for its AI-powered cervical cancer diagnostic support system, Cerviray AI.

This agreement is drawing significant attention for successfully securing an early entry into the Hainan Medical Free Trade Zone in China, a key gateway for global medical devices entering the Chinese market and a region where fast-track regulatory privileges apply.

Using Guorun International Medical Group's Hainan subsidiary (Guorun International Medical & Industry Group Hainan Co., Ltd.) as a base, AIDOT will immediately supply the Cerviray AI system to major medical institutions across the Hainan region and launch full-scale services.

Cerviray AI consists of dedicated cervical imaging hardware (CDC-C02) and an independently developed AI analysis software. Backed by outstanding diagnostic accuracy—featuring 98% sensitivity and 91% specificity—the system precisely assists medical staff in rapid cervical cancer diagnosis and biopsy site selection.

The contract term is 5 years, securing a recurring revenue model based on paid equipment supply alongside annual software subscription fees.

Based on one year of real-world data (RWD) accumulated within the Hainan medical zone, the company plans to proceed smoothly with obtaining medical device approval from China’s National Medical Products Administration (NMPA).

"We have successfully finalized a strategic exclusive agreement for the Hainan region with Guorun International Medical Group, a premier medical device company in China's Hainan Medical Free Trade Zone," said CEO Jae-hoon Jeong. "Full-scale commercial AI services will now commence in the Hainan region, and we will steadily drive forward the Chinese NMPA approval process using our first year of service outcomes."

Source: Korea Economic TV (Reported by Deputy Director Jae-jun Yang | August 11, 2026)

28/07/2026

🌐 AIDOT Supplies AI Cervical Cancer Screening Solution ‘Cerviray AI’ to Andong Hospital
🤝 Enhancing Clinical Workflows and Expanding Domestic Adoption

Andong Hospital has officially adopted AIDOT’s AI-powered cervical cancer screening support solution, Cerviray AI, for its obstetrics and gynecology department.

Cerviray AI is an integrated software and hardware system where an AI, trained on cervical medical images, analyzes screening scans to automatically highlight suspicious lesions and assist medical staff in their reading. Final readings and diagnoses are performed by medical professionals, with the AI serving a supportive role.

The product has received Class 3 medical device approval from the Korean Ministry of Food and Drug Safety (MFDS) and has been designated as an innovative product by the Ministry of Trade, Industry and Energy.

Additionally, it operates on an on-device architecture where patient data is stored locally on hospital devices rather than being transmitted to an external server, ensuring all test data is processed securely within the hospital.

With this deployment, Cerviray AI has been installed in the obstetrics and gynecology clinic at Andong Hospital and is actively utilized in real-world screening settings. The hospital expects the diagnostic support features—such as checking scan images and visually highlighting suspicious lesion locations—to streamline the screening workflow.

"Being able to visually review areas that require closer examination serves as a valuable reference during consultations," said Heung-ryul Kim, Head of Obstetrics and Gynecology at Andong Hospital.

An AIDOT representative stated, "Starting with Andong Hospital, we plan to expand practical deployments to the surrounding Andong region and major hub hospitals in the Gyeongnam area. We are also reviewing plans to accumulate real-world clinical use cases and publish them as research papers in the future."

AIDOT is a specialized medical AI company that develops and supplies medical imaging AI solutions, including cervical cancer screening support.

Source: Korea Economic TV (Reported by Deputy Director Jae-jun Yang | July 28, 2026)

23/07/2026

🌐 Three Years of Impact in Bolivia: AIDOT’s ‘Cerviray AI’
🤝 Over 6,880 Screenings Across 95 Medical Institutions

We are proud to share that AIDOT (CEO Jae-hoon Jeong), through its flagship AI cervical cancer screening system Cerviray AI, has become a cornerstone of public healthcare in Bolivia, reaching 95 medical institutions and recording over 6,880 cumulative screenings.

Initiated three years ago via the KOICA CTS program, this milestone demonstrates how Korean medical AI delivers life-saving solutions to women in the Andes and beyond.

🩺 Overcoming Healthcare Disparities
In Bolivia, cervical cancer is the leading cancer among women, exacerbated by a lack of specialists in rural and high-altitude regions. Cerviray AI bridges this gap by combining a portable digital colposcope with an AI diagnostic algorithm:

High Precision: Backed by 30,000 IRB-approved datasets, achieving 98% sensitivity, 91% specificity, and 93% accuracy (MFDS Class 3 approval).

Offline Capability: Operating seamlessly without connecting to a server, making it ideal for resource-limited environments.

🌍 Sustainable Impact & Latin American Expansion
Following the KOICA project, Cerviray AI continues to operate sustainably with local partner TRIAR. In May 2026, TRIAR donated two units to the Bolivian Cancer Foundation in La Paz, paving the way for broader national expansion.

This success is now accelerating our presence across Latin America:

Mexico & Central America: Clinical trials and approvals underway in Mexico, alongside successful demonstrations in Honduras.

South America: Regulatory processes ongoing in El Salvador and Costa Rica, with 20 units being exported to the National Cancer Institute of Chile.

"Our experience in Bolivia proves that medical AI must build sustainable, local healthcare ecosystems," said CEO Jae-hoon Jeong. "We remain committed to enhancing healthcare access and leading the movement toward a cervical-cancer-free Latin America."

Source: Korea Economic TV (Reported by Deputy Director Jae-jun Yang | July 23, 2026)

10/07/2026

🚀 AIDOT Advances Medical AI at MIDL 2026: Presenting Breakthrough Research in Taipei
🤝 Collaborating with Top-tier University Hospitals to Solve Real-World Clinical Challenges

We are proud to announce that AIDOT recently participated in the Medical Imaging with Deep Learning 2026 (MIDL 2026) in Taiwan. At this prestigious global conference, we presented two research papers developed in close collaboration with leading medical research teams, focusing on on-device AI optimization and advanced anatomical lesion detection.

🩺 1. Empowering Low-Infrastructure Environments with On-Device AI In collaboration with the research teams led by Prof. Jae-Yun Song and Prof. Sung-Min Kim (Korea University Anam Hospital) and Prof. Dong-Hoon Suh (Seoul National University Bundang Hospital), we presented our research on optimizing our cervical cancer screening system, Cerviray AI.
· Key Innovation: By applying knowledge distillation to reduce ViT-Base models to ViT-Tiny and utilizing post-training quantization, we achieved an inference speed of 3.4 seconds per image on a standard CPU (Samsung Galaxy Tab S7).
· Clinical Impact: This breakthrough enables high-performance AI diagnostics in low-income countries or primary care clinics with limited network infrastructure or high-cost server access. Furthermore, performing AI inference locally on the device ensures maximum data privacy and security.

🔍 2. Enhancing Micro-Lesion Detection via Anatomical Context In partnership with the research teams led by Prof. Young-Eun Yoon and Prof. Jae-Hoon Oh (Hanyang University Hospital) and Prof. Dong-Gun Lee (Seoul National University Bundang Hospital), we presented a multi-stage fine-tuning technique for detecting urinary stones in non-contrast CT scans.
· Key Innovation: Utilizing the VISTA3D model, our AI first learns to recognize organs related to urinary stones before applying that anatomical knowledge to stone segmentation.
· Clinical Impact: By teaching the AI to understand the surrounding anatomical context, we significantly improved the detection performance of small, sparse micro-lesions. We plan to integrate these findings into our URO dot AI solution to further elevate its diagnostic precision.

"These studies are the result of our commitment to addressing practical clinical challenges through close collaboration with top medical institutions," said Han-Sol Choi, CTO of AIDOT. "We will continue to advance our research in mobile device optimization and anatomical AI understanding to deliver highly reliable, physician-approved diagnostic support solutions."

We remain dedicated to pushing the boundaries of medical technology and ensuring that our innovations provide real-world value to healthcare providers and patients worldwide.

Source: Korea Economic TV (Reported by Deputy Director Jae-jun Yang | July 10, 2026)

AIDOT

28/09/2026

23/09/2026

16/09/2026

07/09/2026

27/08/2026

13/08/2026

11/08/2026

28/07/2026

23/07/2026

10/07/2026

Address

Website

Alerts

Contact The Business

Shortcuts

Share

Category

Listing takedown request